The latest from Cogstate, leaders in optimizing the measurement of cognition

Snapshot Stocks

January 1, 2013

Business analyst, Trevor Hoey reported on Cogstate in his Snapshot Stocks column regarding Cogstate’s upward share price momentum on the back of a $3.57 million grant awarded for their phase III clinical trial program and securing strong revenues of $8.5 million.

Hoey states, “With an increasing focus on mental health both in Australia and overseas, there should be an increasing demand for Cogstate’s proprietary technology.”